Climb Bio price target raised to $18 from $10 at Oppenheimer

Oppenheimer analyst Leland Gershell raised the firm’s price target on Climb Bio (CLYM) to $18 from $10 and keeps an Outperform rating on the shares ahead of upcoming clinical reveals, which will show how subcutaneous budoprutug as well as CLYM116 perform in healthy volunteers. The firm’s model had not previously included any value for ‘116, in development for IgA nephropathy, yet Oppenheimer views it as exciting as budoprutug, perhaps more so.